Organogenesis Holdings Net Worth
Organogenesis Holdings Net Worth Breakdown | ORGO |
Organogenesis Holdings Net Worth Analysis
Organogenesis Holdings' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Organogenesis Holdings' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Organogenesis Holdings' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Organogenesis Holdings' net worth analysis. One common approach is to calculate Organogenesis Holdings' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Organogenesis Holdings' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Organogenesis Holdings' net worth. This approach calculates the present value of Organogenesis Holdings' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Organogenesis Holdings' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Organogenesis Holdings' net worth. This involves comparing Organogenesis Holdings' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Organogenesis Holdings' net worth relative to its peers.
Enterprise Value |
|
To determine if Organogenesis Holdings is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Organogenesis Holdings' net worth research are outlined below:
| Organogenesis Holdings appears to be risky and price may revert if volatility continues | |
| About 43.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from gurufocus.com: Organogenesis Expands Manufacturing Capacity to Support Future Growth |
Organogenesis Holdings Quarterly Good Will |
|
Organogenesis Holdings uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Organogenesis Holdings. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Organogenesis Holdings' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 6th of March 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 6th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Organogenesis Holdings' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Organogenesis Holdings is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Organogenesis Holdings backward and forwards among themselves. Organogenesis Holdings' institutional investor refers to the entity that pools money to purchase Organogenesis Holdings' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Renaissance Technologies Corp | 2024-09-30 | 817.9 K | Gsa Capital Partners Llp | 2024-09-30 | 773.5 K | D. E. Shaw & Co Lp | 2024-09-30 | 738.1 K | Two Sigma Advisers, Llc | 2024-06-30 | 616.6 K | Northern Trust Corp | 2024-09-30 | 598.9 K | Bank Of America Corp | 2024-06-30 | 496.5 K | Norges Bank | 2024-06-30 | 482.2 K | Connor Clark & Lunn Inv Mgmt Ltd | 2024-06-30 | 446.4 K | Wealth Dimensions Group, Ltd. | 2024-09-30 | 408 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 23.2 M | Soleus Capital Management, L.p. | 2024-06-30 | 11.5 M |
Follow Organogenesis Holdings' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 517.05 M.Market Cap |
|
Project Organogenesis Holdings' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.01 | 0.01 | |
| Return On Capital Employed | 0.03 | 0.03 | |
| Return On Assets | 0.01 | 0.01 | |
| Return On Equity | 0.02 | 0.02 |
When accessing Organogenesis Holdings' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Organogenesis Holdings' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Organogenesis Holdings' profitability and make more informed investment decisions.
Evaluate Organogenesis Holdings' management efficiency
Organogenesis Holdings has return on total asset (ROA) of 0.0164 % which means that it generated a profit of $0.0164 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0266) %, meaning that it created substantial loss on money invested by shareholders. Organogenesis Holdings' management efficiency ratios could be used to measure how well Organogenesis Holdings manages its routine affairs as well as how well it operates its assets and liabilities. As of the 28th of November 2024, Return On Tangible Assets is likely to grow to 0.01. Also, Return On Capital Employed is likely to grow to 0.03. At this time, Organogenesis Holdings' Return On Assets are very stable compared to the past year. As of the 28th of November 2024, Asset Turnover is likely to grow to 1.20, while Total Assets are likely to drop about 292.5 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 2.12 | 2.49 | |
| Tangible Book Value Per Share | 1.78 | 2.08 | |
| Enterprise Value Over EBITDA | 15.31 | 16.08 | |
| Price Book Value Ratio | 1.93 | 1.83 | |
| Enterprise Value Multiple | 15.31 | 16.08 | |
| Price Fair Value | 1.93 | 1.83 | |
| Enterprise Value | 551.7 M | 744.2 M |
At Organogenesis Holdings, effective management practices are pivotal to sustaining long-term profitability. We delve into financial metrics and market conditions to provide a comprehensive analysis of the stock's prospects.
Enterprise Value Revenue 1.183 | Revenue 455 M | Quarterly Revenue Growth 0.061 | Revenue Per Share 3.446 | Return On Equity (0.03) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Organogenesis Holdings insiders, such as employees or executives, is commonly permitted as long as it does not rely on Organogenesis Holdings' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Organogenesis Holdings insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Organogenesis Holdings Corporate Filings
| 27th of November 2024 Other Reports | ViewVerify | |
8K | 22nd of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F3 | 19th of November 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
Organogenesis Holdings Earnings per Share Projection vs Actual
Organogenesis Holdings Corporate Management
| BA Esq | VP Counsel | Profile | |
| Patrick Bilbo | Chief Officer | Profile | |
| Thomas Pearl | Vice Resources | Profile | |
| Zorina Pitkin | VP Systems | Profile | |
| Brian Grow | Chief Officer | Profile | |
| Kurt Matheson | VP Marketing | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Organogenesis Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in Organogenesis Stock, please use our How to Invest in Organogenesis Holdings guide.You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Organogenesis Holdings. If investors know Organogenesis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Organogenesis Holdings listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 3.5 | Earnings Share (0.05) | Revenue Per Share 3.446 | Quarterly Revenue Growth 0.061 | Return On Assets 0.0164 |
The market value of Organogenesis Holdings is measured differently than its book value, which is the value of Organogenesis that is recorded on the company's balance sheet. Investors also form their own opinion of Organogenesis Holdings' value that differs from its market value or its book value, called intrinsic value, which is Organogenesis Holdings' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Organogenesis Holdings' market value can be influenced by many factors that don't directly affect Organogenesis Holdings' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Organogenesis Holdings' value and its price as these two are different measures arrived at by different means. Investors typically determine if Organogenesis Holdings is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Organogenesis Holdings' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.